Amgen drug combination cuts death risk by 58% in aggressive lung cancer trial
🤖 AI-generated content — The title and summary were produced automatically by artificial intelligence, without human editorial review.
Adding Amgen’s Imdelltra to AstraZeneca’s Imfinzi reduced the risk of death by 58% in a late-stage trial involving extensive-stage small cell lung cancer. Median overall survival reached 21.1 months with the maintenance combination, versus 12.7 months with Imfinzi alone.
Continue in the app — vote & join in ➔Source: CNBC Top News · via ahirlevel.hu